Abstract 807P
Background
Ovarian cancer (OC) is the most lethal gynecologic tumor and is characterized by a widespread metastasis in abdominal cavity. Accurate preoperative evaluation is important for the specification of surgical procedures and prediction of surgical outcomes.Currently, a variety of imaging techniques can be used for preoperative evaluation of ovarian cancer such as the Computed Tomography (CT) Suidan score. However, the Magnetic resonance imaging (MRI) based preoperative evaluation was not fully explored. Here, our study explores the feasibility of MRI as a preoperative assessment in OC patients.
Methods
This is a prospective, non-randomized, single-center trial of 134 epithelial ovarian cancer (EOC) patients treated with surgical cytoreduction between 2018 and 2022. All patients underwent preoperative MRI scan. The imaging score consists of lesion size scores in 33 areas of the abdominal cavity.
Results
Complete cytoreduction (CC) was achieved in 81 (60.4%) of 134 patients. CC patients with a median MRI score of 10(4 - 44) and the median MRI score of patients who were incompletely cytoreduced (IC) was 15(5 - 48). By comparing imaging scores with those seen in surgery, we found that MRI evaluation is in good agreement with intraoperative observation. However, for areas such as the small bowel mesentery, the MRI score is lower than the intraoperative score, while for lymph node metastases the MRI score is higher than the intraoperative score. Through multi-factor analysis, we have screened clinical and imaging criteria related to IC including CA125 level, prognostic nutritional index (PNI), diaphragmatic surface of spleen lesion, gallbladder fossa lesion and small bowel mesentery lesion. Based on these criteria, we have constructed preoperative imaging scores and the ‘predictive score’ was assigned to each criterion based on its multivariate OR.
Conclusions
Our research explores the feasibility of incorporating tumor load into MRI based preoperative assessment for OC patients. Also, we identified 5 criteria associated with IC, and developed a predictive model which may be helpful in treatment planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11